Century Therapeutics, Inc. Income Taxes Paid
Century Therapeutics, Inc. (IPSC) reported Income Taxes Paid of $3.89 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaid · last filed 2026-05-13
- Century Therapeutics, Inc. income taxes paid for the quarter ending 2025-03-31 was $2.00K.
- Century Therapeutics, Inc. income taxes paid for the quarter ending 2024-12-31 was $488.00K, a 69.69% decline year-over-year.
- Century Therapeutics, Inc. income taxes paid for the quarter ending 2024-09-30 was -$178.00K.
- Century Therapeutics, Inc. income taxes paid for the quarter ending 2023-12-31 was $1.61M.
- Century Therapeutics, Inc. income taxes paid for fiscal 2025 was $3.89M, a 676.85% increase from fiscal 2024.
- Century Therapeutics, Inc. income taxes paid for fiscal 2024 was $501.00K, a 80.13% decline from fiscal 2023.
- Century Therapeutics, Inc. income taxes paid for fiscal 2023 was $2.52M.
- Century Therapeutics, Inc. income taxes paid for fiscal 2021 was $14.00K.
| Period end | Income Taxes Paid 3 month | Income Taxes Paid 6 month | Income Taxes Paid 9 month | Income Taxes Paid 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.89M 10-K · filed 2026-03-12 | |||
| 2025-03-31 | $2.00K 10-Q · filed 2026-05-13 | $490.00K derived: sum of 2 quarters · filed 2026-05-13 | $312.00K derived: sum of 3 quarters · filed 2026-05-13 | |
| 2024-12-31 | $488.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $310.00K derived: sum of 2 quarters · filed 2026-03-12 | $501.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | -$178.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $13.00K 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $191.00K 10-Q · filed 2025-08-14 | |||
| 2023-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $1.61M derived: sum of 2 quarters · filed 2025-03-19 | $2.52M 10-K · filed 2025-03-19 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $911.00K 10-Q · filed 2024-11-05 | ||
| 2023-06-30 | $911.00K 10-Q · filed 2024-08-08 | |||
| 2021-12-31 | $14.00K 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |